MedTrace Logo

Inflammatory Bowel Disease in South Eastern Norway

NCT02727959 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2286

Last updated 2020-03-05

No results posted yet for this study

Summary

The IBSEN III study will investigate the incidence of inflammatory bowel disease in South Eastern Norway and describe the clinical course of the disease. The investigators will map newly diagnosed and treatment naive IBD patients at various levels (epidemiological, clinical, psychosocial and nutritional as well as immunological, genetic, epigenetic and microbial) as a basis to improve targeted and individualized treatment and care. The investigators will include incident IBD patients at all local- and university hospitals in the South Eastern Health Region in 2016-2018 and follow-up prospectively for five years. The investigators will use standardized and validated registration methods allowing comparability with previous national and international IBD cohorts, link data to national health registries and collect blood, feces and biopsies for bio banking.

Conditions

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • Oslo Metropolitan University

    collaborator OTHER

  • Takeda

    collaborator INDUSTRY

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • Oslo University Hospital

    lead OTHER

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02727959 on ClinicalTrials.gov